Evaluation of EETPAE from Tridax procumbens and Andrographis echioides in The Management of Diabetic Neuropathy

Diabetic neuropathy, a prevalent and debilitating complication of diabetes mellitus, affects up to 50% of individuals over the course of the disease. Its prevalence is influenced by multiple factors, including the type and duration of diabetes, glycemic control, age, lifestyle factors, and genetic predisposition. Global disparities exist, with higher rates reported in developed countries due to differences in healthcare access and disease management. The World Health Organization recognizes diabetic neuropathy as a significant public health concern, given its association with increased morbidity, healthcare utilization, and risk of severe complications such as foot ulcers and cardiovascular disease. The current study investigates the therapeutic potential of EETPAE (Ethanolic Extract of Tridax procumbens and Andrographis echioides) in mitigating symptoms of diabetic neuropathy. EETPAE exhibited significant analgesic, antioxidant, and metabolic regulatory properties. In experimental pain models, the extract improved pain thresholds and reduced inflammation, while biochemical assays revealed restoration of antioxidant enzymes (CAT, SOD, GSH) and reduction of lipid markers such as free fatty acids and total cholesterol. These effects, especially at the high dose (500 mg/kg), were comparable to standard drugs, suggesting the extract’s effectiveness in managing neuropathic pain and metabolic dysregulation. Overall, EETPAE demonstrates promising potential as a natural therapeutic agent for addressing key aspects of diabetic neuropathy, including pain, oxidative stress, and lipid imbalance. Further studies are required to isolate the active compounds and elucidate the molecular mechanisms involved.